Male Reproductive Cancers

Prostate Cancer Drug Resistance Mediated by Epigenetic Changes

Prostate Cancer Drug Resistance Mediated by Epigenetic Changes

By

Epigenetic changes in the tumor microenvironment may explain why prostate cancer patients develop resistance to androgen signaling deprivation therapy.

Study Zeroes in on Cause of Castration-Resistant Prostate Cancer

Study Zeroes in on Cause of Castration-Resistant Prostate Cancer

By

Some prostate cancer cells lack androgen receptors, and they proliferate faster than those that express androgen receptors under androgen-deficient conditions.

Heavy Alcohol Intake in Early Life May Significantly Increase Odds of High-Grade Prostate Cancer

Heavy Alcohol Intake in Early Life May Significantly Increase Odds of High-Grade Prostate Cancer

By

Recent analyses suggest that lifetime intake and early-life alcohol use may significantly contribute to the development of high-grade prostate cancer.

IL-23 Drives Castration-Resistant Prostate Cancer

IL-23 Drives Castration-Resistant Prostate Cancer

By

A growing body of evidence points to infiltrating myeloid-derived suppressor cells as key players in tumor progression and acquired treatment resistance.

SBRT Appears Effective for Oligometastatic Prostate Cancer

SBRT Appears Effective for Oligometastatic Prostate Cancer

By

Stereotactic body radiation therapy achieves good local control of metastases in patients with recurrent prostate cancer following primary treatment.

First-Line Enzalutamide May Confer a Survival Benefit for Metastatic Castration-Resistant Prostate Cancer

First-Line Enzalutamide May Confer a Survival Benefit for Metastatic Castration-Resistant Prostate Cancer

By

Patients may benefit from earlier lines of enzalutamide for the treatment of metastatic castration-resistant prostate cancer.

Active Surveillance May Be a Good Option for Younger Men with Prostate Cancer

Active Surveillance May Be a Good Option for Younger Men with Prostate Cancer

By

The effect of age on outcomes in active surveillance is not well reported and requires further study.

Beverages Sweetened With Added Sugars May Increase the Risk of Prostate Cancer

Beverages Sweetened With Added Sugars May Increase the Risk of Prostate Cancer

By

Some prior evidence has linked increased sugar consumption to cancer development, but its impact on prostate cancer is unknown.

Gene Variant May Affect Response to Abiraterone in Certain Men with Prostate Cancer

Gene Variant May Affect Response to Abiraterone in Certain Men with Prostate Cancer

By

The breakdown of the medication abiraterone, which can be accelerated by the presence of a specific gene variant, produces drug metabolites that are suspected to play a role in the progression of prostate cancer to castration-resistant forms of disease.

FDA Approves Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer

FDA Approves Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer

By

This latest approval now makes enzalutamide the only FDA-approved oral medication indicated for both metastatic and nonmetastatic castration-resistant prostate cancer.

High-Intensity Focused Ultrasound Therapy May Improve Survival in Nonmetastatic Prostate Cancer

High-Intensity Focused Ultrasound Therapy May Improve Survival in Nonmetastatic Prostate Cancer

By

Focal therapy targets may potentially reduce adverse events and provide better cancer control, but previous studies have been limited in scope.

New Therapeutic Directions in the Management of Prostate Cancer

New Therapeutic Directions in the Management of Prostate Cancer

By

According to experts, PARP inhibition, radiopharmaceuticals, and immunotherapy could revolutionize how prostate cancer is treated in the coming decade.

Enzalutamide Postpones Metastasis for a Subset of High-Risk Patients With Prostate Cancer

Enzalutamide Postpones Metastasis for a Subset of High-Risk Patients With Prostate Cancer

By

Treatment with enzalutamide decreased the risk of metastasis or death by 71% in patients diagnosed with nonmetastatic castration-resistant prostate cancer.

Post-Radiotherapy Docetaxel for Intermediate-, High-Risk Prostate Cancer Is Not Beneficial

Post-Radiotherapy Docetaxel for Intermediate-, High-Risk Prostate Cancer Is Not Beneficial

By

A phase 3 trial involving men treated with radiotherapy for intermediate- or high-risk prostate cancer revealed no significant difference in biochemical disease-free survival.

PET/CT Accurately Localizes Recurrent Prostate Cancer

PET/CT Accurately Localizes Recurrent Prostate Cancer

By

Salvage therapy guided by 68Ga-PSMA11 PET/CT resulted in high biochemical response rates.

Abiraterone for mCRPC May Benefit Patients Who Are Black More Than Patients Who Are White

Abiraterone for mCRPC May Benefit Patients Who Are Black More Than Patients Who Are White

By

Abiraterone plus prednisone was associated with significantly greater PSA progression-free survival among patients who are black compared with white patients.

Prostate Cancer Vaccine Found Not To Improve Survival

Prostate Cancer Vaccine Found Not To Improve Survival

By

In a phase 3 trial, Prostvac-V/F did not significantly prolong overall survival among men with asymptomatic or minimally symptomatic mCRPC.

Abiraterone Plus Leuprolide Offers Edge in M0 Hormone-Naive Prostate Cancer

Abiraterone Plus Leuprolide Offers Edge in M0 Hormone-Naive Prostate Cancer

By

Abiraterone plus leuprolide compared with leuprolide decreased the risk of biochemical recurrence by 38%.

Enzalutamide for Advanced Prostate Cancer Does Not Worsen HRQoL

Enzalutamide for Advanced Prostate Cancer Does Not Worsen HRQoL

By

Enzalutamide decreases the risk of clinically meaningful deterioration in HRQoL compared with placebo in men with non-metastatic CRPC, new study finds.

USPSTF 2012 Screening Recommendations May Have Affected Prostate Cancer Testing

USPSTF 2012 Screening Recommendations May Have Affected Prostate Cancer Testing

By

The impact of USPSTF recommendations on the incidence and management of prostate cancer have not yet been fully explored.

Active Surveillance May Be Safe for Selected Men With Gleason 3+4 Prostate Cancer

Active Surveillance May Be Safe for Selected Men With Gleason 3+4 Prostate Cancer

By

Men with Gleason 6 and Gleason 3+4 prostate cancer who undergo radical prostatectomy after a period on active surveillance have similar surgical outcomes.

Prostate Cancer Recurrence Risk Lower With Anterior Tumors

Prostate Cancer Recurrence Risk Lower With Anterior Tumors

By

Following laparoscopic radical prostatectomy, men with posterior index tumors had 76% increased risk of biochemical recurrence vs those with anterior prostate tumors.

Could Diet Adjustment Prevent Aggressive Prostate Cancer?

Could Diet Adjustment Prevent Aggressive Prostate Cancer?

By

A recent article is only the latest in a series of studies drawing attention to the importance of diet in prostate cancer development.

Online Survey May Allow Patients With Prostate Cancer To Accurately Report Comorbidities

Online Survey May Allow Patients With Prostate Cancer To Accurately Report Comorbidities

By

The BMH online survey allows patients to enter comorbidity data at home prior to consultation.

Testicular Cancer Treatment Regimens

Get the latest treatment regimens for testicular cancer, including options such as carboplatin, EP + cisplatin, BEP, and VIP.

Diet and Dosage: How Much Could Patients Save?

Diet and Dosage: How Much Could Patients Save?

By

Knowing that food increases the absorption of some therapies presents the possibility of easily — and significantly — lowering treatment costs.

Adding Mitoxantrone to Adjuvant ADT Not Recommended for High-Risk Prostate Cancer

Adding Mitoxantrone to Adjuvant ADT Not Recommended for High-Risk Prostate Cancer

By

The cause of death was prostate cancer among 18% vs 22% of patients receiving ADT vs ADT plus MP, respectively.

Preventive Benefit of Finasteride for Prostate Cancer Maintained for 16 Years

Preventive Benefit of Finasteride for Prostate Cancer Maintained for 16 Years

By

Results from the Prostate Cancer Prevention Trial indicate that the reduced risk for prostate cancer among men assigned to finasteride continued throughout 16 years of follow-up.

Low-Dose Abiraterone With Low-Fat Meals: Non-Inferior to Standard Dose

Low-Dose Abiraterone With Low-Fat Meals: Non-Inferior to Standard Dose

By

Patients in both treatment arms had a PFS of about 9 months.

Single PSA screening increases prostate cancer detection but does not change mortality

In this randomized controlled trial, men aged 50 to 69 received an invitation to take a single PSA test or were unscreened.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs